Toni Choueiri reports on key results from ESMO Virtual Congress 2020 on 696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial
Produced by ESMO, https://oncologypro.esmo.org